| Size | Price | Stock | Qty |
|---|---|---|---|
| 500μg |
|
||
| 1mg | |||
| Other Sizes |
| Targets |
Ezetimibe hydroxy glucuronide targets the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine. By selectively inhibiting this transporter, it blocks dietary and biliary cholesterol uptake without affecting the absorption of triglycerides or fat-soluble vitamins. This action reduces systemic cholesterol levels and LDL cholesterol.
|
|---|---|
| ln Vitro |
In vitro, Ezetimibe hydroxy glucuronide retains potent cholesterol absorption inhibitory activity by targeting the NPC1L1 transporter. Studies demonstrate that this metabolite circulates systemically and is primarily responsible for the therapeutic effects of ezetimibe. It is used in research to study cholesterol metabolism and the mechanisms of cholesterol absorption inhibition.
|
| ln Vivo |
In vivo, Ezetimibe hydroxy glucuronide is detected in dog and human plasma after oral administration of ezetimibe. It circulates systemically and contributes significantly to the drug's long half-life and cholesterol-lowering efficacy. The metabolite is a key molecule in cardiovascular and lipid metabolism research.
|
| Enzyme Assay |
In vitro assays for Ezetimibe hydroxy glucuronide typically involve studying its interaction with the NPC1L1 transporter using cell-based or membrane-based binding assays. Cholesterol uptake inhibition is measured in cultured intestinal cells (e.g., Caco-2) treated with the compound at concentrations ranging from 0.1-10 µM. The compound's activity is quantified by measuring the uptake of radiolabeled or fluorescent cholesterol analogs.
|
| Cell Assay |
For in vitro cell assays, intestinal epithelial cells (e.g., Caco-2) are cultured and treated with Ezetimibe hydroxy glucuronide at various concentrations. Cholesterol uptake is measured using labeled cholesterol or fluorescent cholesterol analogs. The compound's inhibitory effect on NPC1L1-mediated cholesterol transport is quantified. Cell viability is assessed to ensure the observed effects are not due to cytotoxicity.
|
| Animal Protocol |
For in vivo animal studies, Ezetimibe hydroxy glucuronide is typically administered to rodents or dogs via oral gavage as part of ezetimibe pharmacokinetic studies. Blood samples are collected at various time points, and plasma concentrations of the metabolite are quantified by LC-MS/MS. The compound's systemic exposure, half-life, and contribution to cholesterol-lowering efficacy are evaluated.
|
| ADME/Pharmacokinetics |
Ezetimibe hydroxy glucuronide (MW 585.55) has the molecular formula C30H29F2NO9. It is soluble in water and methanol with purity typically ≥95%. As a phase II glucuronide metabolite, it is more hydrophilic than the parent drug, facilitating systemic circulation and renal elimination. It is stable under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Ezetimibe hydroxy glucuronide is for research use only. No specific toxicity data are available for this metabolite. As the active metabolite of the approved drug ezetimibe, its safety profile is expected to be consistent with that of the parent compound at therapeutic exposures. Standard laboratory safety precautions should be followed.
|
| References |
[1]. Anima Ghosal, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos. 2004 Mar;32(3):314-20.
[2]. Ghosal A, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos. 2004 Mar;32(3):314-20. |
| Additional Infomation |
Ezetimibe hydroxy glucuronide (CAS# 536709-33-8) is the active phase II metabolite of the FDA-approved cholesterol absorption inhibitor ezetimibe. It has not been approved as a standalone therapeutic agent but is a key molecule in cardiovascular and lipid metabolism research. The compound is used in studies of cholesterol absorption, NPC1L1 inhibition, and drug metabolism.
|
| Molecular Formula |
C30H29F2NO9
|
|---|---|
| Molecular Weight |
585.55
|
| Exact Mass |
585.181
|
| CAS # |
536709-33-8
|
| PubChem CID |
49849668
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.547g/cm3
|
| Boiling Point |
863.74ºC at 760 mmHg
|
| Melting Point |
127-129ºC
|
| Flash Point |
476.173ºC
|
| Index of Refraction |
1.68
|
| LogP |
2.869
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
42
|
| Complexity |
921
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)OC5C(C(C(C(O5)C(=O)O)O)O)O)O
|
| InChi Key |
MPXLJVWGRVISEQ-ADEYADIWSA-N
|
| InChi Code |
InChI=1S/C30H29F2NO9/c31-17-5-1-15(2-6-17)22(41-30-26(37)24(35)25(36)27(42-30)29(39)40)14-13-21-23(16-3-11-20(34)12-4-16)33(28(21)38)19-9-7-18(32)8-10-19/h1-12,21-27,30,34-37H,13-14H2,(H,39,40)/t21-,22+,23-,24+,25+,26-,27+,30-/m1/s1
|
| Chemical Name |
(2S,3S,4S,5R,6R)-6-[(1S)-1-(4-fluorophenyl)-3-[(2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxoazetidin-3-yl]propoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7078 mL | 8.5390 mL | 17.0780 mL | |
| 5 mM | 0.3416 mL | 1.7078 mL | 3.4156 mL | |
| 10 mM | 0.1708 mL | 0.8539 mL | 1.7078 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
